The invention relates to new 2-substituted D-homo-estra-1,3,5(10)-trienes of general formula I ##STR00001## in which R.sup.2 means a C.sub.1-C.sub.8-alkyl group, a C.sub.1-C.sub.8-alkyloxy group or a halogen atom, R.sup.13 means a hydrogen atom or a methyl group, R.sup.17 means a hydrogen atom or a fluorine atom, as well as their pharmaceutically acceptable salts, their manufacture and use as medicaments for prophylaxis and therapy of estrogen-dependent diseases that can be influenced by inhibition of 17.beta.-hydroxy steroid dehydro-genase type 1.